Search Results

By Matthew Stenger  / Wednesday, December 18, 2013 10:53 AM

Suboptimal Adverse Event Reporting in Cancer Clinical Trial Publications

In a study reported in the Journal of Clinical Oncology, Sivendran et al assessed the degree to which publication of phase III trials in oncology conformed with CONSORT (Consolidated Standards of Reporting Trials) recommendations for reporting adverse events. They found that adverse event...